Ebru ÜNAL AKOĞLU, Servet ÖZTÜRK, Canan AĞALAR, Eylem Emel ARIKAN

Menopausal transition may affect the onset of HerpesZoster: An update on herpes zoster vaccine

Aim: Herpes zoster (HZ) vaccine maintaining routinely aged ≥60 years due to the debated data on long-term effectiveness. We aimed to evaluate age specific incidence of HZ and possible impact of age and gender differences on the onset of disease to contribute age-appropriate vaccination.Materials and Methods: A total of number 599 patients diagnosed with HZ were evaluated retrospectively. Patients were divided into groups by age. Patients' demographic characteristics, physical examination findings, data of seasonal disease distribution, lesions location, rate of antiviral drug prescription, administered antiviral agent, and presence of accompanying systemic diseases were evaluated.Results: The 599 patients included in this study were 296 (49,4%) male, 308 (50,6%) female and the mean age of total patients was 50.6±18.84 years. There were statistically significant differences between males and females according to the age groups (p=0,006). In addition, the frequency of disease was significantly increased by age (p=0,000). Moreover, HZ incidence peaked in the fifth decade of life and 64,1% of the patients were aged ≥ 45 years. Furthermore, HZ frequency was significantly higher in males (%67.6) than females (%32.4) in aged between 26 to 35 group (p=0,03) and higher in females (%61.7) than males (%38.3) in 46-55 years age group (p=0,012).Conclusion: Sudden menopausal hormone alteration in females between 46 to 55 years of age, may cause an increased frequency of HZ. In this respect, despite current recommendations for vaccinating adults, utilization of HZ vaccine particularly in female patients aged above 45 years may be more beneficial in prevention of disease.

PDF

___

1. Chen SY, Suaya JA, Li Q, et al. Incidence of herpes zoster in patients with altered immune function. Infection 2014;42:325-34.
2. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 2004;4:26-33.
3. Giovanni G, Nicoletta V, Parvane K, et al. Prevention of herpes zoster and its complications: from the clinic to the real-life experience with the vaccine. J Med Microbiol 2016;65:1363-9.
4. Volpi A. Severe complications of herpes zoster. Herpes 2007;14:35-9.
5. Marin M, Marti M, Kambhampati A, et al. Global varicella vaccine effectiveness: a meta-analysis. Pediatrics 2016;137:1-10.
6. Hales CM, Harpaz R, Ortega-Sanchez I, et al. Update on recommendations for use of herpes zoster vaccine. MMWR Surveill Summ 2014;63:729.
7. Johnson BH, Palmer L, Gatwood J, et al. Annual incidence rates of herpes zoster among an immunocompetent population in the United States. BMC Infect Dis 2015;15:502.
8. Lin YH. Varicella-Zoster Working Group; Advisory Committee on Immunization Practices, Taiwan. Disease burden and epidemiology of herpes zoster in pre-vaccine Taiwan. Vaccine 2010;28:1217-20.
9. Fleming DM, Cross KW, Cobb WA, et al. Gender difference in the incidence of shingles. Epidemiol & Infect 2004;132:1-5.
10. Opstelten W, Van Essen GA, Schellevis F, et al. Gender as an independent risk factor for herpes zoster: a population-based prospective study. Ann Epidemiol 2006;16:692-5.
11. Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. The Lancet 2002;360:678-82.
12. Vehid S, Aran SN, Koksal S, et al. The prevalence and the age at the onset of menopause in Turkish women in rural area.Saudi Med J 2006;27:1381-6.
13. Pirincci E, Oguzoncul AF, Tasdemir R. Age at the onset of menopause and its influencing factors in Turkish women in a rural area. J Women Aging 2016;28:238- 246.
14. Gameiro C, Romao F. Changes in the immune system during menopause and aging.Front Biosci (Elite Ed) 2010;2:1299-303.
15. Mimi Ghosh, Marta Rodriguez-Garcia, Charles R. The Immune System in Menopause: Pros and Cons of Hormone Therapy. J Steroid Biochem Mol Biol 2014;0:171-5.
16. Smith JS, Melendy A, Rana RK, et al. Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health 2008;43:5- 25.
17. Duriux-Smith A, TW E, Goodman JT. Comparison of female to male and male to female transmission of HIV in 563 stable couples. Bmj 1992;304:809-13.
18. R. Raz, Urinary tract infection in postmenopausal women, Korean J Urol 2011;52:801-8.
19. Yawn BP, Itzler RF, Wollan PC, et al. Health care utilization and cost burden of herpes zoster in a community population. Mayo Clin Proc 2009;84:787- 94.
20. Forbes HJ, Bhaskaran K, Thomas SL, et al. Quantification of risk factors for herpes zoster: population based case-control study. Bmj 2014;348:2911.
21. Forbes HJ, Bhaskaran K, Thomas SL, et al. Quantification of risk factors for herpes zoster: population based case-control study. Bmj 2014;348:2911.
22. Yawn BP, Saddier P, Wollan PC, et al. A populationbased study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007;82:1341-9.
23. Jih JS, Chen YJ, Lin MW, et al. Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. Acta Derm Venereol 2009;89:612-6.
24. Gallerani M, Manfredini R. Seasonal variation in herpes zoster infection. Br J Dermatol 2000;142:588-9.
25. Brănişteanu DE, Stoleriu G, Oanţă A, et al. Clinicalepidemiological trends of herpes zoster: a 5-year study. Rev Med Chir Soc Med Nat Iasi 2014;118:817- 22.
26. Jung HS, Kang JK, Yoo SH. Epidemiological Study on the Incidence of Herpes Zoster in Nearby Cheonan. Korean J Pain 2015;28:193-7.
27. Kawai K, Yawn BP, Wollan P, et al. Increasing incidence of herpes zoster over a 60-year period from a population-based study. Clin Infect Dis 2016;63:221- 6.
28. Rachana R, Shivaswamy KN, Anuradha HV. A study on clinical characteristics of herpes zoster in a tertiary care center. Int J Res 2017;3:79.
29. Gabutti G, Valente N, Kuhdari P, et al. Prevention of Herpes Zoster and its complications: from the clinic to the real life experience with the vaccine. J Med Microbiol 2016;65:1363-9.